137 related articles for article (PubMed ID: 20043982)
1. A novel method for the production of crystalline micronised particles.
Muhammad SA; Langrish T; Tang P; Adi H; Chan HK; Kazarian SG; Dehghani F
Int J Pharm; 2010 Mar; 388(1-2):114-22. PubMed ID: 20043982
[TBL] [Abstract][Full Text] [Related]
2. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
Corrigan DO; Corrigan OI; Healy AM
Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
[TBL] [Abstract][Full Text] [Related]
4. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
Müller T; Krehl R; Schiewe J; Weiler C; Steckel H
Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680
[TBL] [Abstract][Full Text] [Related]
5. Optimisation of powders for pulmonary delivery using supercritical fluid technology.
Rehman M; Shekunov BY; York P; Lechuga-Ballesteros D; Miller DP; Tan T; Colthorpe P
Eur J Pharm Sci; 2004 May; 22(1):1-17. PubMed ID: 15113578
[TBL] [Abstract][Full Text] [Related]
6. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery.
Dhumal RS; Biradar SV; Paradkar AR; York P
Int J Pharm; 2009 Feb; 368(1-2):129-37. PubMed ID: 18996462
[TBL] [Abstract][Full Text] [Related]
7. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders.
Raula J; Lähde A; Kauppinen EI
Int J Pharm; 2009 Jan; 365(1-2):18-25. PubMed ID: 18789380
[TBL] [Abstract][Full Text] [Related]
8. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
9. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry.
Gaisford S; Dennison M; Tawfik M; Jones MD
Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222
[TBL] [Abstract][Full Text] [Related]
10. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
[TBL] [Abstract][Full Text] [Related]
11. Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate.
Shariare MH; de Matas M; York P
Int J Pharm; 2011 Aug; 415(1-2):62-72. PubMed ID: 21683128
[TBL] [Abstract][Full Text] [Related]
12. Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process.
Thakur R; Gupta RB
Int J Pharm; 2006 Feb; 308(1-2):190-9. PubMed ID: 16352406
[TBL] [Abstract][Full Text] [Related]
13. Can low-dose combination products for inhalation be formulated in single crystalline particles?
Kumon M; Kwok PC; Adi H; Heng D; Chan HK
Eur J Pharm Sci; 2010 Apr; 40(1):16-24. PubMed ID: 20172026
[TBL] [Abstract][Full Text] [Related]
14. Predicting the physical state of spray dried composites: salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems.
Corrigan DO; Corrigan OI; Healy AM
Int J Pharm; 2004 Apr; 273(1-2):171-82. PubMed ID: 15010141
[TBL] [Abstract][Full Text] [Related]
15. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
[TBL] [Abstract][Full Text] [Related]
16. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
Thi TH; Danède F; Descamps M; Flament MP
Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
[TBL] [Abstract][Full Text] [Related]
17. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation.
Chiou H; Li L; Hu T; Chan HK; Chen JF; Yun J
Int J Pharm; 2007 Feb; 331(1):93-8. PubMed ID: 17052870
[TBL] [Abstract][Full Text] [Related]
18. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders.
Raula J; Thielmann F; Naderi M; Lehto VP; Kauppinen EI
Int J Pharm; 2010 Jan; 385(1-2):79-85. PubMed ID: 19879344
[TBL] [Abstract][Full Text] [Related]
19. Carbomer-modified spray-dried respirable powders for pulmonary delivery of salbutamol sulphate.
Alhusban FA; Seville PC
J Microencapsul; 2009 Aug; 26(5):444-55. PubMed ID: 18855201
[TBL] [Abstract][Full Text] [Related]
20. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate.
Young PM; Price R
Eur J Pharm Sci; 2004 Jul; 22(4):235-40. PubMed ID: 15196579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
